Bioaffinity Technologies Inc (BIAF)

May 03, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 03, 2026

Apr 30, 2026

bioAffinity Shareholders Approve Equity Plan and Capital Measures - TipRanks

Apr 30, 2026

Apr 30, 2026

Investors in bioAffinity (NASDAQ: BIAF) register 497,483 shares for resale - Stock Titan

Apr 30, 2026

Apr 30, 2026

bioAffinity Technologies (BIAF) wins approval for major equity plan, offerings and reverse split - Stock Titan

Apr 30, 2026

Apr 30, 2026

BioAffinity stock surges 113.8% in 3 months: What's driving the rally? - MSN

Apr 30, 2026

Apr 29, 2026

bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment - BioSpace

Apr 29, 2026

Apr 28, 2026

BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss - MSN

Apr 28, 2026

Apr 28, 2026

BIAF stock gains as CyPath sales surge 146% in Q1 - MSN

Apr 28, 2026

Apr 23, 2026

bioAffinity Technologies prices $4.8 million public offering; shares down over 30% - MSN

Apr 23, 2026

Apr 22, 2026

bioAffinity Technologies Working With U.S. Army on CyPath Lung Study - Medical Product Outsourcing

Apr 22, 2026

Apr 20, 2026

BioAffinity (BIAF) Stock in Focus Today (Volatility Increases) 2026-04-20Trading Community - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Apr 18, 2026

BioAffinity shares rise as CyPath Lung growth boosts optimism - MSN

Apr 18, 2026

Apr 16, 2026

BioAffinity (BIAF) Stock Slides (Breakdown Watch) 2026-04-16Shared Momentum Picks - Cổng thông tin điện tử Tỉnh Sơn La

Apr 16, 2026

Apr 16, 2026

bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally? - The Globe and Mail

Apr 16, 2026

Apr 15, 2026

New Case Study Shows bioAffinity Technologies CyPath Lung Diagnostic Helps Avoid Unnecessary Lung Biopsy - National Today

Apr 15, 2026

Apr 15, 2026

CyPath® Lung Diagnostic Helps Defer Unnecessary Biopsy - National Today

Apr 15, 2026

Apr 15, 2026

New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy - BioSpace

Apr 15, 2026

Apr 14, 2026

New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, P - PharmiWeb.com

Apr 14, 2026

Apr 14, 2026

bioAffinity Highlights CyPath Lung Case Avoiding Unnecessary Biopsy - TipRanks

Apr 14, 2026

Apr 14, 2026

CyPath Lung case study at bioAffinity (NASDAQ: BIAF) shows biopsy deferred - Stock Titan

Apr 14, 2026

Apr 14, 2026

UGRO, TURB, ANNA, EEIQ, BIAF: These five stocks outpaced big tech with massive March returns - MSN

Apr 14, 2026

Apr 13, 2026

Institution Moves: Can bioAffinity Technologies Inc lead its sector in growth2026 Trading Volume Trends & Weekly Watchlist of Top Performers - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Investment Review: Is bioAffinity Technologies Inc Equity Warrant stock overvalued or fairly priced2026 Buyback Activity & Technical Pattern Based Buy Signals - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

BIAF PE Ratio & Valuation, Is BIAF Overvalued - Intellectia AI

Apr 12, 2026

Apr 10, 2026

Wall Street Recap: Can bioAffinity Technologies Inc Equity Warrant outperform under higher oil pricesMarket Performance Report & Low Drawdown Investment Ideas - baoquankhu1.vn

Apr 10, 2026

Apr 10, 2026

Jobs Data: What hedge funds are buying bioAffinity Technologies Inc Equity WarrantWeekly Trading Summary & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn

Apr 10, 2026

Apr 10, 2026

What is the volatility of BioAffinity (BIAF) Stock | Price at $3.54, Up 6.66%Growth Investing - Cổng thông tin điện tử Tỉnh Sơn La

Apr 10, 2026

Apr 09, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Apr 09, 2026

Apr 07, 2026

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early - PharmiWeb.com

Apr 07, 2026

Apr 07, 2026

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16 - BioSpace

Apr 07, 2026

Apr 07, 2026

bioAffinity Showcases CyPath Lung Test at Cleveland Clinic - TipRanks

Apr 07, 2026

Apr 07, 2026

CyPath Lung spotlight for bioAffinity Technologies (Nasdaq: BIAF) - Stock Titan

Apr 07, 2026

Apr 06, 2026

Risk Analysis: What are the future prospects of bioAffinity Technologies Inc Equity Warrant2026 Trading Recap & Community Consensus Trade Signals - baoquankhu1.vn

Apr 06, 2026

Apr 06, 2026

Is BioAffinity (BIAF) Stock Showing Strength | Price at $3.88, Down 1.02%Hot Market Picks - Cổng thông tin điện tử Tỉnh Sơn La

Apr 06, 2026

Apr 04, 2026

BIAFW Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Apr 04, 2026

Apr 03, 2026

BIAF Stock Gains As CyPath Sales Surge 146% In Q1 - stocktwits.com

Apr 03, 2026

Apr 03, 2026

BIAF Should I Buy - Intellectia AI

Apr 03, 2026

Apr 02, 2026

bioAffinity Technologies, Inc.Common Stock (NQ: BIAF - The Chronicle-Journal

Apr 02, 2026

Apr 02, 2026

BIAF Stock Price $3.76 | bioAffinity Technologies, Inc. Live Quote - Meyka

Apr 02, 2026

Apr 02, 2026

bioAffinity reports 146% jump in Q1 lung test sales By Investing.com - Investing.com South Africa

Apr 02, 2026